Skip to main content

In Case You Thought Biotech ETF’s Plunge Couldn’t Get Worse...

  • Author:
  • Updated:

A foul wind blows south from here.

It can and did, obviously. Already down about 15% since last Friday, the iShares Nasdaq Biotechnology ETF showed that it was still a biotech ETF yesterday, riding the sector’s swoon to its worst day ever to punctuate its worst seven days ever.

The $809 million SPDR S&P Pharmaceuticals exchange-traded fund (XPH) shed 8.4%, while the iShares Nasdaq Biotechnology ETF (IBB) dropped 6.3%.

The formerly high-flying biotechnology ETF has now lost 20% over the past seven trading sessions….

One trader said that the selling “feels heavily index driven,” meaning that investors are bailing on index-tracking exchange-traded funds — and fast. Trading volume in the IBB hit a record 11.7 million shares on Monday, topping its previous record — 9 million — hit on Friday.

Capitulation In Biotech? ETF Suffers Biggest One-Day Drop Since 2011 [WSJ MoneyBeat blog]
Dow Industrials Sink 313 Points [WSJ]


By ETF Group / ETF Ride Systems ( [Public domain], via Wikimedia Commons

Ticker Symbol ETF Was Available. There Was Only One Thing To Do.

Have you ever wanted to own all 37 ETF provider stocks but didn't feel like putting in the work?